Trypanosoma cruzi-Specific T-Cell Responses to Monitor Treatment Efficacy in Chronic Chagas Disease.

[1]  R. Tarleton,et al.  Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes , 2018, Front. Immunol..

[2]  R. Tarleton,et al.  Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses , 2016, PLoS neglected tropical diseases.

[3]  Graham M Lord,et al.  Immune biomarkers: the promises and pitfalls of personalized medicine , 2015, Nature Reviews Immunology.

[4]  M. Teixeira,et al.  Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease , 2012, Seminars in Immunopathology.

[5]  R. Tarleton,et al.  Impact of Aetiological Treatment on Conventional and Multiplex Serology in Chronic Chagas Disease , 2011, PLoS neglected tropical diseases.

[6]  Z. Yadón,et al.  Chagas disease: a Latin American health problem becoming a world health problem. , 2010, Acta tropica.

[7]  R. Tarleton,et al.  Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  R. Gazzinelli,et al.  The role of parasite persistence in pathogenesis of Chagas heart disease , 2009, Parasite immunology.

[9]  R. Tarleton,et al.  Chronic Human Infection with Trypanosoma cruzi Drives CD4+ T Cells to Immune Senescence1 , 2009, The Journal of Immunology.

[10]  E. Segura,et al.  Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. , 2009, Memorias do Instituto Oswaldo Cruz.

[11]  D. B. Weatherly,et al.  High Throughput Selection of Effective Serodiagnostics for Trypanosoma cruzi infection , 2008, PLoS neglected tropical diseases.

[12]  J. Sidney,et al.  HLA Class I-T Cell Epitopes from trans-Sialidase Proteins Reveal Functionally Distinct Subsets of CD8+ T Cells in Chronic Chagas Disease , 2008, PLoS neglected tropical diseases.

[13]  Robert H Gilman,et al.  Evaluation and treatment of chagas disease in the United States: a systematic review. , 2007, JAMA.

[14]  R. Tarleton.  Immune system recognition of Trypanosoma cruzi. , 2007, Current opinion in immunology.

[15]  D. Fabbro,et al.  Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. , 2007, Revista da Sociedade Brasileira de Medicina Tropical.

[16]  R. Tarleton,et al.  Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. , 2006, International immunology.

[17]  P. Gutierrez,et al.  Acute Chagas’ disease: immunohistochemical characteristics of T cell infiltrate and its relationship with T. cruzi parasitic antigens. , 2005, Acta cardiologica.

[18]  R. Tarleton,et al.  Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. , 2004, The Journal of infectious diseases.

[19]  R. Tarleton.  Chagas disease: a role for autoimmunity? , 2003, Trends in parasitology.

[20]  Héctor Freilij,et al.  Anticuerpos Anti-F2/3 como marcador de curación en niños con infección congenita por Trypanosoma Cruzi , 2003 .

[21]  A. Eggermont,et al.  Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. , 2000, Journal of immunological methods.

[22]  H. Masur,et al.  Trypanosoma cruzi meningoencephalitis in HIV-infected patients. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[23]  E. Segura,et al.  Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. , 1998, The American journal of tropical medicine and hygiene.

[24]  A. McMichael,et al.  Rapid Effector Function in CD8+ Memory T Cells , 1997, The Journal of experimental medicine.

[25]  L. Glimcher,et al.  Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease. , 1996, International immunology.

[26]  E. Segura,et al.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. , 1994, American heart journal.

[27]  S. Rosemberg,et al.  Fatal meningoencephalitis caused by reactivation of Trypanosoma cruzi infection in a patient with AIDS , 1992, Neurology.